AstraZeneca gains EU approval for asthma drug, boosting growth outlook with strong pipeline and oncology focus

AstraZeneca PLC has received EU approval for its asthma treatment Trixeo Aerosphere, expanding its market in Respiratory & Immunology. The company leverages mid-single-digit revenue growth into stronger earnings per share gains, driven by its oncology segment and robust pipeline execution. Despite some late-stage setbacks, AstraZeneca's pipeline momentum with multiple positive Phase III results and approvals supports its long-term growth. The company maintains guidance for mid-to-high single-digit revenue growth and low double-digit EPS growth, trading at a reasonable valuation reflecting its quality and pipeline strength.

AstraZeneca trades at USD 166.03 on Pluang as of Sep 25, 2026 20:32 WIB, up 0.89% for the day. The stock's market cap stands at $254.58 billion with a dividend yield of 1.95%. Despite 75% of Pluang orders being sell orders, the typical hold time is 125 days, indicating steady investor interest.